Log in

NASDAQ:MEDS - MultiCell Technologies Stock Price, Forecast & News

-0.44 (-6.78 %)
(As of 03/27/2020 04:00 PM ET)
Today's Range
Now: $6.05
50-Day Range N/A
52-Week Range
Now: $6.05
Volume69,942 shs
Average Volume191,836 shs
Market Capitalization$39.57 million
P/E RatioN/A
Dividend YieldN/A
Trxade Group, Inc. owns and operates a business-to-business Web-based marketplace focused on the pharmaceutical industry in the United States. It operates through Trxade, Inc.; Community Specialty Pharmacy, LLC; and Other segments. The company operates a Web based market platform that enables commerce among healthcare buyers and sellers of pharmaceuticals, accessories, and services. Its principal products and services include Trxade.com, a Web-based pharmaceutical marketplace; InventoryRx.com, a Web-based pharmaceutical exchange platform; Pharmabayonline that provides proprietary pharmaceutical data analytics and governmental reimbursement benchmarks analysis to the United States-based independent pharmacies and pharmaceutical databases; and RxGuru, a desktop application, which provides product information. The company also operates a retail specialty pharmacy. In addition, it operates Delivmeds.com, a consumer-based app to provide delivery of pharmaceutical products; and Trxademso.com to assist independent retail pharmacies on pricing, distribution, and logistics. Trxade Group, Inc. is based in Land O'Lakes, Florida.
Read More

Industry, Sector and Symbol

Industry Drugs, proprietaries, & sundries
Current SymbolNASDAQ:MEDS



Sales & Book Value

Annual Sales$3.83 million
Cash Flow$0.00 per share
Book Value$0.16 per share


Net Income$10,000.00


Market Cap$39.57 million
Next Earnings Date3/31/2020 (Estimated)
OptionableNot Optionable

Receive MEDS News and Ratings via Email

Sign-up to receive the latest news and ratings for MEDS and its competitors with MarketBeat's FREE daily newsletter.

MultiCell Technologies (NASDAQ:MEDS) Frequently Asked Questions

How has MultiCell Technologies' stock been impacted by COVID-19 (Coronavirus)?

MultiCell Technologies' stock was trading at $4.96 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, MEDS shares have increased by 22.0% and is now trading at $6.05. View which stocks have been mosted impacted by Coronavirus.

When is MultiCell Technologies' next earnings date?

MultiCell Technologies is scheduled to release its next quarterly earnings announcement on Tuesday, March 31st 2020. View our earnings forecast for MultiCell Technologies.

Has MultiCell Technologies been receiving favorable news coverage?

Media headlines about MEDS stock have trended somewhat positive this week, InfoTrie Sentiment Analysis reports. The research firm ranks the sentiment of media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. MultiCell Technologies earned a news impact score of 0.8 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the company's share price in the near future. View the latest news aboutMultiCell Technologies.

Who are some of MultiCell Technologies' key competitors?

What other stocks do shareholders of MultiCell Technologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other MultiCell Technologies investors own include Inovio Pharmaceuticals (INO), Allied Healthcare Products (AHPI), Francesca's (FRAN), Gilead Sciences (GILD), Alphabet (GOOG), Heat Biologics (HTBX), Micron Technology (MU), Ollie's Bargain Outlet (OLLI), Opko Health (OPK) and Roku (ROKU).

Who are MultiCell Technologies' key executives?

MultiCell Technologies' management team includes the following people:
  • Mr. Surendra K. Ajjarapu, Founder, Chairman, CEO, Treasurer & Sec. (Age 49)
  • Mr. Prashant Patel, Founder, Pres, COO & Director (Age 46)
  • Mr. Howard A. Doss, Chief Financial Officer (Age 66)
  • Dr. Ramesh Kenchappa M.S.(Pharma), Ph.D., Chief Scientific Officer
  • Mr. Steven D. Lee Esq., Gen. Counsel

What is MultiCell Technologies' stock symbol?

MultiCell Technologies trades on the NASDAQ under the ticker symbol "MEDS."

When did MultiCell Technologies' quiet period expire?

MultiCell Technologies' quiet period expired on Tuesday, March 24th. MultiCell Technologies had issued 806,452 shares in its initial public offering on February 13th. The total size of the offering was $5,241,938 based on an initial share price of $6.50. During MultiCell Technologies' quiet period, underwriters and any insiders involved in the IPO were restricted from issuing any research reports or earnings estimates for the company because of SEC regulations. Now that the company's quiet period has ended, brokerages that served as underwriters are now able to initiate research on the company.

How do I buy shares of MultiCell Technologies?

Shares of MEDS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is MultiCell Technologies' stock price today?

One share of MEDS stock can currently be purchased for approximately $6.05.

How big of a company is MultiCell Technologies?

MultiCell Technologies has a market capitalization of $39.57 million and generates $3.83 million in revenue each year. MultiCell Technologies employs 31 workers across the globe. View additional information about MultiCell Technologies.

What is MultiCell Technologies' official website?

The official website for MultiCell Technologies is http://www.trxade.com/.

How can I contact MultiCell Technologies?

MultiCell Technologies' mailing address is 3840 Land O' Lakes Blvd., Land O' Lakes FL, 34639. The company can be reached via phone at 800-261-0281 or via email at [email protected]

MarketBeat Community Rating for MultiCell Technologies (NASDAQ MEDS)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  4 (Vote Outperform)
Underperform Votes:  4 (Vote Underperform)
Total Votes:  8
MarketBeat's community ratings are surveys of what our community members think about MultiCell Technologies and other stocks. Vote "Outperform" if you believe MEDS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MEDS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/28/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel